Skip to main content

Table 1 Baseline characteristics of the patients in the two parts of the study

From: Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial

   Part II: Double-Blind
  Part I: Safety rhEPO (n = 13) rhEPO (n = 21) Placebo (n = 19) f
Age (years; median, range) 68(21–78) 68(39–80) 63(49–79) n.s.
Sex (male/female) 8/5 15/6 13/6 n.s.
Hemisphere (left/right) 5/8 11/10 10/9 n.s.
Stroke subtype     
Cardioembolic 6 9 10 n.s.
Small vessel occlusive 4 3 3 n.s.
Large vessel occlusive 1 5 4 n.s.
Other 2 4 2 n.s.
ASA pretreatment 7 5 9 n.s.
Stroke scales     
SSS (median, range) 31(9–46) 30(8–52) 30(6–54) n.s.
NIHSS (median, range) 12(4–27) 11(3–26) 11(1–28) n.s.
Imaging     
DWI (cm3; mean ± SEM) 40.1 ± 11.8 35.4 ± 8.0 n.s.
FLAIR (cm3; mean ± SEM) 14.1 ± 8.5 3.8 ± 1.3 n.s.
Mean arterial blood pressure 122(109–145) 127(91–150) 130(100–177) n.s.
(mm Hg; median, range)     
CRP (U/I; mean ± SEM) 4.3 ± 0.8 13.3 ± 6.6 9.0 ± 4.6 n.s.
Glucose (mg%; mean ± SEM) 146.7 ± 19.9 123.5 ± 8.7 137.2 ± 14.0 n.s.
Time to treatment (h:min) (median, range) 6:20(3:30–8:00) 5:00(2:40–7:55) 4:45(3:20–7:45) n.s.